How to Cite
Abstract
An overwhelming number of new agents, including targeted agents with unique mechanisms of action, are available in oncology practice today. Along with the benefit of new treatments for patients comes the unfamiliarity of associated toxicities and learning the best methods to minimize side effects. Side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of targeted, multikinase inhibitors.
References
Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management // J Am Acad Dermatol. 2007;56:317–326.
Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions // Oncologist. 2010;15:1002–1008.
Sanmartin O. Skin Manifestations of Targeted Antineoplastic Therapy // Curr. Probl. Dermatol. Basel, Karger. 2018;53:93–104. doi:10.1159/000479198
Osio A, Mateus C, Soria J.C et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors // Br. J. Dermatol. 2009;161:515–521.
Reguiai Z, Bachet JB, Bachmeyer C et al. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm // Support Care Cancer. 2012;20:1395–1404.
Califano R, Tariq N, Compton S et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK // Drugs 2015;75:1335–1348.
Королева И.А., Болотина Л.В., Гладков О.А. и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Злокачественные опухоли: Практические рекомендации RUSSCO. 2019;9(3s2):628–638 [Koroleva IA, Bolotina LV, Gladkov OA et al. Practical recommendations for drug treatment of dermatological reactions in patients receiving anticancer drug therapy // Malignant Tumors: Practical Guidelines RUSSCO. 2019;9(3s2):628–638 (In Russ.)].
Macdonald JB, Macdonald B, Golitz LE et al. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane // J. Am. Acad. Dermatol. 2015;72:203–218:219–220.
Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events // Oncology (Williston Park). 2006;20(5 suppl. 2):5–13.
Shi VJ, Levy LL, Choi JN. Cutaneous manifestations of nontargeted and targeted chemotherapies // Semin. Oncol. 2016;43:419–425.
Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced handfoot skin reaction: a review of clinical presentation, pathogenesis, and management // Am. J. Clin. Dermatol. 2016;17:387–402.
Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib // Br J Dermatol. 2009;161:1045–1051.
Севрюков Ф. С., Бородавина Е. В., Исаев П. А. и др. Нежелательные кожные реакции на применение мультикиназных ингибиторов в лечении рака щитовидной железы. Опухоли головы и шеи 2020;10(4):44–9 [Sevryukov F. S., Borodavina E. V., Isaev P. A. et al. Side skin reactions of multikinase inhibitors in treatment of thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2020;10(4):44–9 (In Russ.)]. DOI: 10.17650/2222-1468-2020-10-4-44-49.
Снеговой А.В., Болотина Л.В., Горбунова В.А. и др. Практические рекомендации по коррекции дерматологических реакций у пациентов, получающих терапию EGFR // Злокачественные опухоли: Практические рекомендации. 2016:433. doi:10.18027/2224-5057-2016-4s2-428-433 [Snegovoi AV, Bolotina LV, Gorbunova VA et al. Practical recommendations for correction of dermatological reactions in patients receiving EGRF therapy // Practical Guidelines. 2016:433(In Russ.)]. doi:10.18027/2224-5057-2016-4s2-428-433
Guerra JR, Suelves AM, Bella A, Lolo D. Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy // BMJ Case Rep. 2014;2014:pii:bcr2013202822.
Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management // J Am Acad Dermatol. 2007;56:317–326.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy // J. Am. Acad. Dermatol. 2014;71:217.e1–e217.e11;quiz 227–228.
Hsiao YW, Lin YC, Hui RC, Yang CH. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma // J Clin Oncol. 2011;29:e340–e341.
Sanmartin O. Skin Manifestations of Targeted Antineoplastic Therapy. Curr. Probl. Derma Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy // J. Am. Acad. Dermatol. 2014;71:217.e1–e217.e11;quiz 227–228.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022